Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about VKTX stock here.
Medical Marketing & Media3h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Health Care Down on Rotation Back to Risk — Health Care Roundup
Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...
Zacks Investment Research on MSN4h
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
WebMD22h
How to Lose Weight While Eating More Food
One of the most common pitfalls to weight loss is an all-or-nothing approach aimed at dropping pounds in a hurry. When you start an unrealistic diet plan, you quickly learn that such diets lead to ...